Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTaichung Veterans General Hospital

About this trial

Aims:

To investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination.

Methods:

In this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep.

In addition, patients' characteristics will be investigated as follows:

1. Sociodemographic factors (ethnicity, age, sex, body weight, BMI, blood pressure) 2. Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle) 3. Anxiety, evaluate by Hospital Anxiety and Depression Scale (HADS) 4. Depression, evaluate by Beck's Depression Inventory 5. Quality of life, evaluate by 36-Item Short Form Survey (SF-36) 6. Quality of sleep, evaluate by Pittsburgh Sleep Quality Index (PSQI) 7. Aura of headache 8. Episodic or chronic headache (If patient diagnosed as migraine.) 9. Nausea, vomiting, photophobia, phonophobia (If patient diagnosed as migraine.) During the following time, we will need the patient's blood samples four times, each times 20cc, all need 80cc for Lab test of MMP2, CGRP, substance P, beta-endorphin.

Importance:

In our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Migraine patient under the diagnosis and classification of headache was evaluated using the ICHD-3 criteria.

Disqualifiers

Age under 18 years old

Pregnancy

Trial design

Design model

Crossover

Treatments tested in this trial

  • Laser Pen

    Device

    Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)

  • Observation

    Other intervention

    Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3) After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Laser treatmentExperimental treatment 1 intervention
Group B: Sham treatmentSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

cGRP

change in cGRP from baasline and each follow-up time point

Time frame
12 weeks, 24 weeks, 36 weeks
2

MMP2

change in MMP2 from baasline and each follow-up time point

Time frame
12 weeks, 24 weeks, 36 weeks

Secondary outcomes

1

Difference in the number of headache days per month

change in monthly migraine days (MMD) from baseline and each follow-up time point

Time frame
12 weeks, 24 weeks, 36 weeks
2

Difference in the of headache attacks lasting hours per month

change in acute headache medications usage days per month from baseline and each follow-up time point

Time frame
12 weeks, 24 weeks, 36 weeks
3

Difference in the headache pain intensity (NRS)

changes in the headache severity (based on NRS) between baseline and each follow-up time point

Time frame
12 weeks, 24 weeks, 36 weeks
4

Difference in the number of days with acute headache medication intake per month

change in acute headache medications usage days per month from baseline and each follow-up time point

Time frame
12 weeks, 24 weeks, 36 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.